CorMedix reaffirms 2026 revenue guidance of $325-345M; CMS sets Q1 2027 DefenCath Add-on at $8.32 per session

CorMedix Inc.

Unaudited cash and cash equivalents of approximately $355 million as of September 30, 2026; full Q3 results to be discussed on a November 12, 2026 call.
Reaffirmed August 2026 full-year 2026 total revenue guidance of $325 million to $345 million.
CMS's October 28, 2026 ESRD PPS final rule set the Q1 2027 DefenCath post-TDAPA Add-on at $8.32 per dialysis session, 3.5x the current $2.37 rate.
CorMedix expects the Add-on to decline in Q2 2027 versus Q1, then rise in Q3 and/or Q4, with the full-year 2027 average above 2x the current $2.37.
Company said it provided no utilization or pricing data to any large dialysis organization; third-party 2027 Add-on projections are not CorMedix guidance.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.